Sheila Rodriguez-Stanley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sheila Rodriguez-Stanley has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Malcolm G. Robinson
9 shared publicationsPhilip B. Miner
9 shared publicationsSattar Zubaidi
7 shared publications- Jerry D. Gardner
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Redwood City, USA
6 shared publications Jay A. Barth
3 shared publicationsSheldon Sloan
3 shared publications
Latest Publications
- 1 September 2006
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 38 (9) , 1659-1665
Effect of Esophageal Acid and Prophylactic Rabeprazole on Performance in Runners
Acid reflux occurs during exercise. The effects of esophageal acid and prophylactic antisecretory treatment on exercise performance are unknown. To determine 1) the effect of esophageal acid perfusion during exercise on pulmonary function and exercise performance, and 2) whether acid suppression with rabeprazole (RAB) 20 mg x d(-1) increases exercise performance during esophageal acid infusion. This was a two-phase study. Twenty-four conditioned runners (11 with heartburn, 13 without) completed phase 1. Sixteen runners with heartburn completed phase 2 (RAB). For phase 1, esophageal evaluation, baseline maximum exertion test, and a standard Bruce protocol maximal stress test were performed. Runners were randomized to sham esophageal infusion (NG tube placed in the distal esophagus, no fluid) or esophageal acid perfusion (0.1 N HCl perfused) during exercise. Subjects were crossed over to the alternate perfusion. For phase 2, runners underwent three sessions with both acid and sham perfusion during running; the sessions were randomly conducted on different days at baseline and 8 and 12 wk of RAB 20 mg. For phase 1, esophageal function and sensitivity were normal. There was no difference in airway resistance or work capacity between groups. The acid-perfusion group significantly decreased time to exhaustion in the no-heartburn group (23.13 to 20.66 min) with a decrease in energy expenditure. For phase 2, time to exhaustion was significantly decreased with acid perfusion at all time points (P < 0.05). Total energy expenditure during exercise was less in each acid-perfusion test. No difference in pulmonary function was present at week 12 versus baseline. Esophageal acid perfusion decreased performance. In runners with heartburn, suppression of endogenous acid secretion did not improve exercise performance. Changes in cardiopulmonary function do not explain the decreased exercise performance during acid perfusion.
- 1 September 2006
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 38 (9) , 1659-1665
Effect of Esophageal Acid and Prophylactic Rabeprazole on Performance in Runners
Acid reflux occurs during exercise. The effects of esophageal acid and prophylactic antisecretory treatment on exercise performance are unknown. To determine 1) the effect of esophageal acid perfusion during exercise on pulmonary function and exercise performance, and 2) whether acid suppression with rabeprazole (RAB) 20 mg x d(-1) increases exercise performance during esophageal acid infusion. This was a two-phase study. Twenty-four conditioned runners (11 with heartburn, 13 without) completed phase 1. Sixteen runners with heartburn completed phase 2 (RAB). For phase 1, esophageal evaluation, baseline maximum exertion test, and a standard Bruce protocol maximal stress test were performed. Runners were randomized to sham esophageal infusion (NG tube placed in the distal esophagus, no fluid) or esophageal acid perfusion (0.1 N HCl perfused) during exercise. Subjects were crossed over to the alternate perfusion. For phase 2, runners underwent three sessions with both acid and sham perfusion during running; the sessions were randomly conducted on different days at baseline and 8 and 12 wk of RAB 20 mg. For phase 1, esophageal function and sensitivity were normal. There was no difference in airway resistance or work capacity between groups. The acid-perfusion group significantly decreased time to exhaustion in the no-heartburn group (23.13 to 20.66 min) with a decrease in energy expenditure. For phase 2, time to exhaustion was significantly decreased with acid perfusion at all time points (P < 0.05). Total energy expenditure during exercise was less in each acid-perfusion test. No difference in pulmonary function was present at week 12 versus baseline. Esophageal acid perfusion decreased performance. In runners with heartburn, suppression of endogenous acid secretion did not improve exercise performance. Changes in cardiopulmonary function do not explain the decreased exercise performance during acid perfusion.
- 1 June 2006
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (12) , 1719-1724
Effect of naproxen on gastric acid secretion and gastric pH
Summary: Background: The mechanisms for the non‐steroidal anti‐inflammatory drug‐induced inflammation in the stomach are unclear.Aims: To determine if naproxen (Naprosyn, Roche, Nutley, NJ, USA) alters basal acid output, pentagastrin‐stimulated maximal acid output, or fasting gastrin.Methods: Basal acid output and maximal acid output gastric aspirations were performed pre‐naproxen and 7 days post‐naproxen 500 mg b.d. in 24 healthy subjects. Volume, pH and acid mEq were determined. Fasting gastrin was obtained. Comparisons were made using paired t‐tests (α = 0.05).Results: Dosing with naproxen did not statistically decrease mean pH of the basal acid output gastric fluid (3.3 vs. 3.1; N.S.) or the pentagastrin‐stimulated maximal acid output gastric fluid (2.7 vs. 2.6; N.S.). Basal acid output total volume was significantly decreased post‐naproxen (84 vs. 61 mL/h; P = 0.01), with no change in maximal acid output total volume (196 vs. 188 mL/h; N.S.). Basal acid output mean gastric acidity was significantly increased post‐naproxen (0.04 vs. 0.05 mEq/mL; P = 0.03), with no change in maximal acid output mean gastric acidity after naproxen (0.10 vs. 0.10; N.S.). Gastrin was not altered by dosing with naproxen.Conclusions: Naproxen does not influence total acid secreted but does decrease basal gastric fluid volume, thereby increasing basal gastric acid concentration. These observations define one mechanism by which non‐steroidal anti‐inflammatory drugs may induce gastric injury.
- 1 June 2006
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (12) , 1719-1724
Effect of naproxen on gastric acid secretion and gastric pH
Summary: Background: The mechanisms for the non‐steroidal anti‐inflammatory drug‐induced inflammation in the stomach are unclear.Aims: To determine if naproxen (Naprosyn, Roche, Nutley, NJ, USA) alters basal acid output, pentagastrin‐stimulated maximal acid output, or fasting gastrin.Methods: Basal acid output and maximal acid output gastric aspirations were performed pre‐naproxen and 7 days post‐naproxen 500 mg b.d. in 24 healthy subjects. Volume, pH and acid mEq were determined. Fasting gastrin was obtained. Comparisons were made using paired t‐tests (α = 0.05).Results: Dosing with naproxen did not statistically decrease mean pH of the basal acid output gastric fluid (3.3 vs. 3.1; N.S.) or the pentagastrin‐stimulated maximal acid output gastric fluid (2.7 vs. 2.6; N.S.). Basal acid output total volume was significantly decreased post‐naproxen (84 vs. 61 mL/h; P = 0.01), with no change in maximal acid output total volume (196 vs. 188 mL/h; N.S.). Basal acid output mean gastric acidity was significantly increased post‐naproxen (0.04 vs. 0.05 mEq/mL; P = 0.03), with no change in maximal acid output mean gastric acidity after naproxen (0.10 vs. 0.10; N.S.). Gastrin was not altered by dosing with naproxen.Conclusions: Naproxen does not influence total acid secreted but does decrease basal gastric fluid volume, thereby increasing basal gastric acid concentration. These observations define one mechanism by which non‐steroidal anti‐inflammatory drugs may induce gastric injury.
- 1 April 2006
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (4) , 442-450
Effect of Tegaserod on Esophageal Pain Threshold, Regurgitation, and Symptom Relief in Patients With Functional Heartburn and Mechanical Sensitivity
- 1 April 2006
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (4) , 442-450
Effect of Tegaserod on Esophageal Pain Threshold, Regurgitation, and Symptom Relief in Patients With Functional Heartburn and Mechanical Sensitivity
- 1 January 2005
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 50 (1) , 81-85
Esophageal Visceral Sensitivity to Bile Salts in Patients with Functional Heartburn and in Healthy Control Subjects
Patients with nonerosive gastroesophageal reflux disease often have relatively low esophageal acid exposure and respond suboptimally to gastric acid suppression. In these patients, other constituents of gastric contents may induce esophageal symptoms. We have demonstrated that gastric contents can cause heartburn when the gastric pH > 4. (Aliment Pharm Ther 14:129–134, 2000). The aim of this study was to determine relative sensitivities to chenodeoxycholic and ursodeoxycholic acids, and 0.1 N HCl, administered as provocative perfusion tests. Patients with functional heartburn and healthy control subjects were evaluated. Patients underwent a modified Bernstein acid infusion test and esophageal Barostat balloon distention. Time and volume to pain were recorded. Barostat balloon distention was performed using our standard protocol. Stepwise distentions were performed and pain was recorded. Sensitivity to chenodeoxycholic acid (Cheno) and Ursodeoxycholic acid (Urso) were assessed similarly to the Bernstein test using 2 mM concentrations of each, followed immediately by 5 mM if no pain was reported with 2 mM. Volume of bile acid infusion and length of time until pain was induced were assessed and compared to the same endpoints for acid sensitivity. “Total” time and “total” volume to induce pain were calculated for Cheno and Urso. Least-squares means were generated and two-tailed t-tests and regression analyses were performed (P < 0.05 level of significance). Ten functional heartburn patients and six healthy controls were evaluated (3 M, 13 F; age range, 19 to 56 years). Since five of six controls had pain with acid infusion (hypersensitive), all subjects were analyzed as one group. Only three subjects (all controls) had no pain with infusion of 2 mM Cheno and received the follow-up infusion of 5 mM. These same three subjects tolerated the maximum infusion (150 ml and 15 min) of 5 mM Cheno. Nine subjects did not have pain with 2 mM Urso and received the follow-up infusion of 5 mM Urso (five functional heartburn, four controls). Significantly more subjects tolerated the maximum bile acid infusion of 2 mM Urso vs 2 mM Cheno (nine vs three; P < 0.05, Chi-square test). The pain threshold (volume and time) for Urso was significantly higher than that for Cheno and acid (P < 0.05), and the pain threshold for Cheno was significantly higher than that for acid (P < 0.05). Conclusions are as follows: (1) Bile acids differ in their ability to induce pain. (2) Changing bile acid composition by treatment with Urso may change symptom presentation and symptom severity in patients with bile acid-induced esophageal pain.
- 1 January 2005
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 50 (1) , 81-85
Esophageal Visceral Sensitivity to Bile Salts in Patients with Functional Heartburn and in Healthy Control Subjects
Patients with nonerosive gastroesophageal reflux disease often have relatively low esophageal acid exposure and respond suboptimally to gastric acid suppression. In these patients, other constituents of gastric contents may induce esophageal symptoms. We have demonstrated that gastric contents can cause heartburn when the gastric pH > 4. (Aliment Pharm Ther 14:129–134, 2000). The aim of this study was to determine relative sensitivities to chenodeoxycholic and ursodeoxycholic acids, and 0.1 N HCl, administered as provocative perfusion tests. Patients with functional heartburn and healthy control subjects were evaluated. Patients underwent a modified Bernstein acid infusion test and esophageal Barostat balloon distention. Time and volume to pain were recorded. Barostat balloon distention was performed using our standard protocol. Stepwise distentions were performed and pain was recorded. Sensitivity to chenodeoxycholic acid (Cheno) and Ursodeoxycholic acid (Urso) were assessed similarly to the Bernstein test using 2 mM concentrations of each, followed immediately by 5 mM if no pain was reported with 2 mM. Volume of bile acid infusion and length of time until pain was induced were assessed and compared to the same endpoints for acid sensitivity. “Total” time and “total” volume to induce pain were calculated for Cheno and Urso. Least-squares means were generated and two-tailed t-tests and regression analyses were performed (P < 0.05 level of significance). Ten functional heartburn patients and six healthy controls were evaluated (3 M, 13 F; age range, 19 to 56 years). Since five of six controls had pain with acid infusion (hypersensitive), all subjects were analyzed as one group. Only three subjects (all controls) had no pain with infusion of 2 mM Cheno and received the follow-up infusion of 5 mM. These same three subjects tolerated the maximum infusion (150 ml and 15 min) of 5 mM Cheno. Nine subjects did not have pain with 2 mM Urso and received the follow-up infusion of 5 mM Urso (five functional heartburn, four controls). Significantly more subjects tolerated the maximum bile acid infusion of 2 mM Urso vs 2 mM Cheno (nine vs three; P < 0.05, Chi-square test). The pain threshold (volume and time) for Urso was significantly higher than that for Cheno and acid (P < 0.05), and the pain threshold for Cheno was significantly higher than that for acid (P < 0.05). Conclusions are as follows: (1) Bile acids differ in their ability to induce pain. (2) Changing bile acid composition by treatment with Urso may change symptom presentation and symptom severity in patients with bile acid-induced esophageal pain.
- 1 November 2004
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 49 (11-12) , 1862-1867
Calcium Carbonate Antacids Alter Esophageal Motility in Heartburn Sufferers
Chewed calcium carbonate (CaCO3) rapidly neutralizes esophageal acid and may prevent reflux, suggesting another mechanism of action independent of acid neutralization. Calcium is essential for muscle tone. Our aim was to determine if luminal calcium released from chewed antacids improved esophageal motor function in heartburn sufferers. Esophageal manometry and acid clearance (swallows and time to raise esophageal pH to 5 after a 15-ml 0.1 N HCl bolus) were performed in 18 heartburn sufferers before and after chewing two Tums EX (1500 mg CaCO3, 600 mg calcium). Subjects with hypertensive esophageal contractions or hypertensive lower esophageal sphincter pressure (LESP) were excluded. Subjects with normal to low LESP were included. Differences between parameters were determined by two-tailed paired t-tests, P &< 0.05. Proximal esophageal contractile amplitude was significantly increased after CaCO3 (47.18 vs 52.97 mm Hg; P = 0.02), distal onset velocity was significantly decreased after CaCO3 (4.34 vs 3.71 cm/sec; P = 0.02), and acid clearance was significantly increased 30 min after CaCO3 (20.35 vs 11.7 swallows, [P &< 0.005] and 12.19 vs 6.29 min [P &< 0.007]). LESP was not altered after CaCO3 (22.70 vs 23.79 mm Hg; P = 0.551), however, LESP increased in 9 of 18 subjects. Depth of LES relaxation, medial and distal esophageal contractile amplitude, and duration of contractions were not altered by CaCO3. CaCO3 did not alter salivary secretion and pH in a subset of these subjects, and CaCO3 with secreted saliva did not neutralize a 15-ml acid bolus. The Ca2+ released after chewing of CaCO3 antacids may be partially responsible for the reduction of heartburn by significantly improving initiation of peristalsis and acid clearance.
- 1 November 2004
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 49 (11-12) , 1862-1867
Calcium Carbonate Antacids Alter Esophageal Motility in Heartburn Sufferers
Chewed calcium carbonate (CaCO3) rapidly neutralizes esophageal acid and may prevent reflux, suggesting another mechanism of action independent of acid neutralization. Calcium is essential for muscle tone. Our aim was to determine if luminal calcium released from chewed antacids improved esophageal motor function in heartburn sufferers. Esophageal manometry and acid clearance (swallows and time to raise esophageal pH to 5 after a 15-ml 0.1 N HCl bolus) were performed in 18 heartburn sufferers before and after chewing two Tums EX (1500 mg CaCO3, 600 mg calcium). Subjects with hypertensive esophageal contractions or hypertensive lower esophageal sphincter pressure (LESP) were excluded. Subjects with normal to low LESP were included. Differences between parameters were determined by two-tailed paired t-tests, P &< 0.05. Proximal esophageal contractile amplitude was significantly increased after CaCO3 (47.18 vs 52.97 mm Hg; P = 0.02), distal onset velocity was significantly decreased after CaCO3 (4.34 vs 3.71 cm/sec; P = 0.02), and acid clearance was significantly increased 30 min after CaCO3 (20.35 vs 11.7 swallows, [P &< 0.005] and 12.19 vs 6.29 min [P &< 0.007]). LESP was not altered after CaCO3 (22.70 vs 23.79 mm Hg; P = 0.551), however, LESP increased in 9 of 18 subjects. Depth of LES relaxation, medial and distal esophageal contractile amplitude, and duration of contractions were not altered by CaCO3. CaCO3 did not alter salivary secretion and pH in a subset of these subjects, and CaCO3 with secreted saliva did not neutralize a 15-ml acid bolus. The Ca2+ released after chewing of CaCO3 antacids may be partially responsible for the reduction of heartburn by significantly improving initiation of peristalsis and acid clearance.
- 21 October 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (9) , 975-982
A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn
Summary: Background : The rapid onset and symptomatic response to histamine‐2 receptor antagonists prior to the pharmacological effect on acid secretion suggests a different mechanism of action.Aim : To determine if ranitidine decreases oesophageal sensitivity to chemical and mechanical stimulation, potentially via oesophageal histamine receptors.Methods : A total of 18 patients with functional heartburn received oral ranitidine 150 mg b.d. or placebo for 7 consecutive days in a double‐blind randomized crossover design and underwent Barostat balloon distention and Bernstein acid infusion on study day 1 (90 min postdose) and study day 7. First sensation and pain were recorded and pain severity was rated on a 5‐point Likert scale and a 100 mm visual analogue scale. Least square mean values were generated and one‐tailed t‐tests were performed.Results : After a single dose of ranitidine 150 mg, time to pain with oesophageal acid infusion was increased by 29% (P < 0.05) and visual analogue scale and Likert scores were decreased by 20% (P < 0.06) and 23% (P < 0.02), respectively compared with placebo. After 1 week of ranitidine, positive alterations in sensory parameters persisted. Balloon distention sensory parameters were not altered by ranitidine.Conclusions : Ranitidine significantly decreased oesophageal sensitivity to acid. Failure of ranitidine to improve balloon sensory parameters supports existence of multiple sensory pathways in the oesophagus.
- 21 October 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (9) , 975-982
A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn
Summary: Background : The rapid onset and symptomatic response to histamine‐2 receptor antagonists prior to the pharmacological effect on acid secretion suggests a different mechanism of action.Aim : To determine if ranitidine decreases oesophageal sensitivity to chemical and mechanical stimulation, potentially via oesophageal histamine receptors.Methods : A total of 18 patients with functional heartburn received oral ranitidine 150 mg b.d. or placebo for 7 consecutive days in a double‐blind randomized crossover design and underwent Barostat balloon distention and Bernstein acid infusion on study day 1 (90 min postdose) and study day 7. First sensation and pain were recorded and pain severity was rated on a 5‐point Likert scale and a 100 mm visual analogue scale. Least square mean values were generated and one‐tailed t‐tests were performed.Results : After a single dose of ranitidine 150 mg, time to pain with oesophageal acid infusion was increased by 29% (P < 0.05) and visual analogue scale and Likert scores were decreased by 20% (P < 0.06) and 23% (P < 0.02), respectively compared with placebo. After 1 week of ranitidine, positive alterations in sensory parameters persisted. Balloon distention sensory parameters were not altered by ranitidine.Conclusions : Ranitidine significantly decreased oesophageal sensitivity to acid. Failure of ranitidine to improve balloon sensory parameters supports existence of multiple sensory pathways in the oesophagus.
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A221
Ranitidine 150 MG rapidly increases pain threshold and decreases symptom severity with acid infusion in patients with functional heartburn
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A221
Ranitidine 150 MG rapidly increases pain threshold and decreases symptom severity with acid infusion in patients with functional heartburn
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A482-A483
Endoscopy-negative GERD is a gastric ‘hypersecretory’ disorder
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A482-A483
Endoscopy-negative GERD is a gastric ‘hypersecretory’ disorder
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A482
Meal-induced heartburn: Quantification of esophageal acid exposure and its relationship to gastric acidity
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A482
Meal-induced heartburn: Quantification of esophageal acid exposure and its relationship to gastric acidity
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A479-479
Competitive distance running increases gastroesophageal reflux
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A479-479
Competitive distance running increases gastroesophageal reflux